133 related articles for article (PubMed ID: 28798096)
1. Activation of tissue plasminogen activator by metastasis-inducing S100P protein.
Clarke CJ; Gross SR; Ismail TM; Rudland PS; Al-Medhtiy M; Santangeli M; Barraclough R
Biochem J; 2017 Sep; 474(19):3227-3240. PubMed ID: 28798096
[TBL] [Abstract][Full Text] [Related]
2. The Role of the C-Terminal Lysine of S100P in S100P-Induced Cell Migration and Metastasis.
Ismail TM; Gross SR; Lancaster T; Rudland PS; Barraclough R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680103
[TBL] [Abstract][Full Text] [Related]
3. S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer.
Hsu YL; Hung JY; Liang YY; Lin YS; Tsai MJ; Chou SH; Lu CY; Kuo PL
Oncotarget; 2015 Oct; 6(30):29585-98. PubMed ID: 26320193
[TBL] [Abstract][Full Text] [Related]
4. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients.
Wang G; Platt-Higgins A; Carroll J; de Silva Rudland S; Winstanley J; Barraclough R; Rudland PS
Cancer Res; 2006 Jan; 66(2):1199-207. PubMed ID: 16424059
[TBL] [Abstract][Full Text] [Related]
5. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.
Novokhatny V; Medved L; Lijnen HR; Ingham K
J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771
[TBL] [Abstract][Full Text] [Related]
6. Identification of the interplay between SOX9 and S100P in the metastasis and invasion of colon carcinoma.
Shen Z; Deng H; Fang Y; Zhu X; Ye GT; Yan L; Liu H; Li G
Oncotarget; 2015 Aug; 6(24):20672-84. PubMed ID: 26009899
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin-1 promotes colorectal cancer invasion and metastasis through crosstalk with S100P.
Lin F; Zhang P; Zuo Z; Wang F; Bi R; Shang W; Wu A; Ye J; Li S; Sun X; Wu J; Jiang L
Cancer Lett; 2017 Aug; 401():1-10. PubMed ID: 28483515
[TBL] [Abstract][Full Text] [Related]
8. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
9. Oligomerization and divalent ion binding properties of the S100P protein: a Ca2+/Mg2+-switch model.
Gribenko AV; Makhatadze GI
J Mol Biol; 1998 Oct; 283(3):679-94. PubMed ID: 9784376
[TBL] [Abstract][Full Text] [Related]
10. S100P promotes pancreatic cancer growth, survival, and invasion.
Arumugam T; Simeone DM; Van Golen K; Logsdon CD
Clin Cancer Res; 2005 Aug; 11(15):5356-64. PubMed ID: 16061848
[TBL] [Abstract][Full Text] [Related]
11. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
12. Accelerated fibrinolysis and its propagation on vascular endothelial cells by secreted and retained tPA.
Urano T; Suzuki Y
J Biomed Biotechnol; 2012; 2012():208108. PubMed ID: 23118500
[TBL] [Abstract][Full Text] [Related]
13. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Jankun J; Merrick HW; Goldblatt PJ
J Cell Biochem; 1993 Oct; 53(2):135-44. PubMed ID: 8227186
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin.
Sorrell AM; Shand JH; Tonner E; Gamberoni M; Accorsi PA; Beattie J; Allan GJ; Flint DJ
J Biol Chem; 2006 Apr; 281(16):10883-9. PubMed ID: 16505491
[TBL] [Abstract][Full Text] [Related]
15. Calcium-binding protein S100P and cancer: mechanisms and clinical relevance.
Jiang H; Hu H; Tong X; Jiang Q; Zhu H; Zhang S
J Cancer Res Clin Oncol; 2012 Jan; 138(1):1-9. PubMed ID: 21947242
[TBL] [Abstract][Full Text] [Related]
16. S100P dissociates myosin IIA filaments and focal adhesion sites to reduce cell adhesion and enhance cell migration.
Du M; Wang G; Ismail TM; Gross S; Fernig DG; Barraclough R; Rudland PS
J Biol Chem; 2012 May; 287(19):15330-44. PubMed ID: 22399300
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the predictive efficiency of S100P on adverse prognosis and the pathogenesis of S100P-mediated invasion and metastasis of colon adenocarcinoma.
Shen ZY; Fang Y; Zhen L; Zhu XJ; Chen H; Liu H; Jiang B; Li GX; Deng HJ
Cancer Genet; 2016 Apr; 209(4):143-53. PubMed ID: 26975699
[TBL] [Abstract][Full Text] [Related]
18. Myelin basic protein stimulates plasminogen activation via tissue plasminogen activator following binding to independent l-lysine-containing domains.
Gonzalez-Gronow M; Fiedler JL; Farias Gomez C; Wang F; Ray R; Ferrell PD; Pizzo SV
Biochem Biophys Res Commun; 2017 Aug; 490(3):855-860. PubMed ID: 28648598
[TBL] [Abstract][Full Text] [Related]
19. Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers.
Sharma MC
Int J Cancer; 2019 May; 144(9):2074-2081. PubMed ID: 30125343
[TBL] [Abstract][Full Text] [Related]
20. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
